Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Main billing specialties: cardiology and electrophysiology.
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 252 | 13,475−2.8%/yr | −2.8%/yr | 6.31.2× | 8% | 13,600 in 2030+0.2%/yr |
| California | 239 | 12,086−4.4%/yr | −4.4%/yr | 3.70.7× | 4% | 12,400 in 2030+0.5%/yr |
| Texas | 220 | 11,944−3.2%/yr | −3.2%/yr | 5.81.1× | 7% | 12,500 in 2030+0.7%/yr |
| New York | 148 | 8,138−3%/yr | −3%/yr | 4.70.9× | 0% | 8,390 in 2030+0.5%/yr |
| Pennsylvania | 147 | 7,396−2.8%/yr | −2.8%/yr | 5.61.1× | 2% | 6,810 in 2030−1.4%/yr |
| Illinois | 127 | 6,690−0.8%/yr | −0.8%/yr | 5.01.0× | 4% | 6,500 in 2030−0.5%/yr |
| Ohio | 116 | 5,350−4.9%/yr | −4.9%/yr | 5.01.0× | 0% | 5,520 in 2030+0.5%/yr |
| Virginia | 89 | 5,169−2.2%/yr | −2.2%/yr | 5.11.0× | 6% | 5,360 in 2030+0.6%/yr |
| North Carolina | 100 | 4,907−3.4%/yr | −3.4%/yr | 5.21.0× | 0% | 5,080 in 2030+0.6%/yr |
| New Jersey | 86 | 4,680−4.6%/yr | −4.6%/yr | 4.60.9× | 0% | 4,910 in 2030+0.8%/yr |
| Tennessee | 79 | 4,585−3.7%/yr | −3.7%/yr | 6.81.3× | 1% | 4,450 in 2030−0.5%/yr |
| Georgia | 88 | 4,562−3.7%/yr | −3.7%/yr | 5.51.1× | 0% | 5,000 in 2030+1.5%/yr |
| Michigan | 80 | 4,354−7%/yr | −7%/yr | 5.41.1× | 1% | 3,930 in 2030−1.7%/yr |
| Massachusetts | 90 | 4,351−1.6%/yr | −1.6%/yr | 4.70.9× | 0% | 4,910 in 2030+2%/yr |
| Indiana | 79 | 4,130−1.9%/yr | −1.9%/yr | 6.11.2× | 0% | 4,280 in 2030+0.6%/yr |
| Arizona | 85 | 4,095−2.6%/yr | −2.6%/yr | 5.71.1× | 26% | 4,390 in 2030+1.2%/yr |
| South Carolina | 68 | 3,818−0.9%/yr | −0.9%/yr | 5.81.1× | 1% | 4,480 in 2030+2.7%/yr |
| Missouri | 69 | 3,704−3.1%/yr | −3.1%/yr | 6.21.2× | 1% | 3,900 in 2030+0.9%/yr |
| Maryland | 50 | 3,380−1.5%/yr | −1.5%/yr | 3.90.8× | 1% | 3,330 in 2030−0.2%/yr |
| Washington | 61 | 2,895−4.3%/yr | −4.3%/yr | 3.90.8× | 0% | 2,950 in 2030+0.3%/yr |
| Minnesota | 54 | 2,678−1.9%/yr | −1.9%/yr | 6.21.2× | 2% | 3,620 in 2030+5.2%/yr |
| Wisconsin | 51 | 2,533−2.6%/yr | −2.6%/yr | 4.70.9× | 0% | 2,880 in 2030+2.1%/yr |
| Arkansas | 40 | 2,434−5.8%/yr | −5.8%/yr | 6.71.3× | 0% | 2,160 in 2030−1.9%/yr |
| Alabama | 51 | 2,358−6.8%/yr | −6.8%/yr | 5.61.1× | 0% | 2,180 in 2030−1.3%/yr |
| Oklahoma | 41 | 2,342−5.8%/yr | −5.8%/yr | 5.01.0× | 3% | 2,290 in 2030−0.4%/yr |
| Kansas | 48 | 2,322−5%/yr | −5%/yr | 5.91.2× | 13% | 2,470 in 2030+1%/yr |
| Louisiana | 38 | 2,141−6.6%/yr | −6.6%/yr | 5.51.1× | 9% | 1,980 in 2030−1.3%/yr |
| Kentucky | 43 | 2,124−7.2%/yr | −7.2%/yr | 4.81.0× | 0% | 1,980 in 2030−1.2%/yr |
| Colorado | 38 | 1,903−1.6%/yr | −1.6%/yr | 4.10.8× | 0% | 2,210 in 2030+2.5%/yr |
| Iowa | 34 | 1,666−1.9%/yr | −1.9%/yr | 3.90.8× | 0% | 1,710 in 2030+0.5%/yr |
| Connecticut | 40 | 1,648−4.1%/yr | −4.1%/yr | 5.21.0× | 0% | 1,830 in 2030+1.8%/yr |
| Mississippi | 27 | 1,618−8.6%/yr | −8.6%/yr | 4.50.9× | 6% | 1,500 in 2030−1.3%/yr |
| Oregon | 32 | 1,588−2.2%/yr | −2.2%/yr | 4.00.8× | 3% | 1,810 in 2030+2.2%/yr |
| Nebraska | 20 | 1,389−4%/yr | −4%/yr | 5.51.1× | 4% | 1,420 in 2030+0.4%/yr |
| Nevada | 21 | 1,111−3%/yr | −3%/yr | 4.00.8× | 2% | 1,240 in 2030+1.8%/yr |
| West Virginia | 18 | 1,108−1.5%/yr | −1.5%/yr | 5.51.1× | 0% | 1,020 in 2030−1.4%/yr |
| Utah | 22 | 921−2.8%/yr | −2.8%/yr | 4.40.9× | 0% | 900 in 2030−0.4%/yr |
| Montana | 15 | 883+1.5%/yr | +1.5%/yr | 4.70.9× | 0% | 880 in 20300%/yr |
| Idaho | 16 | 883+3.2%/yr | +3.2%/yr | 4.50.9× | 0% | 1,260 in 2030+6.1%/yr |
| New Hampshire | 18 | 814−0.4%/yr | −0.4%/yr | 3.70.7× | 0% | 1,020 in 2030+3.7%/yr |
| Delaware | 13 | 724−4.8%/yr | −4.8%/yr | 4.30.9× | 0% | 790 in 2030+1.4%/yr |
| New Mexico | 11 | 618−2.3%/yr | −2.3%/yr | 2.80.5× | 0% | 670 in 2030+1.3%/yr |
| South Dakota | 8 | 587−1.6%/yr | −1.6%/yr | 4.70.9× | 0% | 750 in 2030+4.1%/yr |
| Maine | 16 | 574−6.2%/yr | −6.2%/yr | 3.80.7× | 0% | 530 in 2030−1.4%/yr |
| North Dakota | 10 | 559−1.6%/yr | −1.6%/yr | 5.81.1× | 0% | 640 in 2030+2.2%/yr |
| District of Columbia | 10 | 494−2.1%/yr | −2.1%/yr | 8.11.6× | 0% | 510 in 2030+0.4%/yr |
| Rhode Island | 9 | 460−6.3%/yr | −6.3%/yr | 5.31.0× | 0% | 500 in 2030+1.4%/yr |
| Vermont | 10 | 413+2.4%/yr | +2.4%/yr | 3.70.7× | 0% | 710 in 2030+9.3%/yr |
| Alaska | 6 | 384−0.5%/yr | −0.5%/yr | 3.20.6× | 26% | 440 in 2030+2.2%/yr |
| Wyoming | 3 | 122+2.7%/yr | +2.7%/yr | 1.10.2× | 0% | 190 in 2030+7.7%/yr |
| Hawaii | 3 | 114−16%/yr | −16%/yr | 0.90.2× | 0% | 130 in 2030+2.8%/yr |
Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 4,204 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 6 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 1,975 |
| Boston Scientific | 1,012 |
| Abbott | 656 |
| Biotronik | 478 |
| Microport Crm | 72 |
| Great Batch Medical | 11 |
Product codes: DTB (permanent pacemaker electrode), DXY (implantable pacemaker pulse-generator), LWP (implantable pulse generator, pacemaker (non-crt)), LWS (implantable cardioverter defibrillator (non-crt)), MRM (defibrillator, implantable, dual-chamber), NIK (defibrillator, automatic implantable cardioverter, with cardiac resynchronization (crt-d)), NKE (pulse generator, pacemaker, implantable, with cardiac resynchronization (crt-p)), NVN (drug eluting permanent right ventricular (rv) or right atrial (ra) pacemaker electrodes), NVY (permanent defibrillator electrodes), PNJ (leadless pacemaker). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 13% of the cases CMS names in Florida; 139 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| EP ablation | 2,323 | 129,831+7.2%/yr | +7.2%/yr | 241,600 in 2030+11%/yr |
| LAA occlusion & loop recorders | 2,939 | 120,836+10%/yr | +10%/yr | 217,900 in 2030+10%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 12 companies reported engagement with surgeons in the covered states worth $13M in consulting, speaking, meals and travel tied to these products, about $4,338 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.